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Chronic treatment of hydroxytryptamine type 2a
receptor antagonist sarpogrelate hydrochloride
modulates the vasoreactivity of serotonin in
experimental rabbit vein grafts
Akio Kodama, MD, PhD,a Kimihiro Komori, MD, PhD,a Junko Kajikuri, PhD,b and
Takeo Itoh, PhD,b Nagoya City, Japan
Objective: It has been suggested that 5-hydroxytryptamine (5-HT) plays a role in the pathogenesis of vein graft spasms. It is
suggested that smooth muscle 5-HT2A and 5-HT1B receptors contribute to 5-HT-induced contraction, while endothelial
5-HT1B receptors contribute to the 5-HT-induced endothelium-mediated relaxation. We recently found that chronic
administration of the selective 5-HT2A receptor antagonist sarpogrelate hydrochloride (SH) enhances the function of
endothelium-derived nitric oxide (NO) in rabbit vein grafts. However, it is unknown if such treatment modulates 5-HT-
induced vasospasm in vein grafts, and if so, what the underlying mechanisms are.
Methods: Male rabbits were divided into two groups: a control group and an SH-treated group. The jugular vein was
interposed in the carotid artery in reversed fashion. Isometric tension was examined using vein grafts after 4 weeks.
5-HT (108 -106M)-induced contractionwas obtained in each group in the absence or presence of theNOsynthase inhibitor
l-NG-nitroarginine (L-NNA). The expression of 5-HT2A and 5-HT1B receptors was examined immunohistochemically.
Results: The 5-HT induced a concentration-dependent contractions in both groups. L-NNA did not significantly modify the
5-HT-induced contraction in the control group but enhanced it in the SH group. The 5-HT1B receptor antagonist GR55562
inhibited the 5-HT-induced contraction in the control group, while it increased the sensitivity of contraction to 5-HT in the
SH-treated group in the absence (but not in the presence) of L-NNA. Positive immunoreactivities against 5-HT1B and 5-HT2A
receptors were identified in endothelial and medial regions of vein grafts in both groups, and the expression of 5-HT2A
receptors (but not 5-HT1B receptors) was significantly less in the SH-treated group than in the control group.
Conclusion:Chronically administered SH to rabbits upregulates the autoinhibitorymechanism by 5-HT through a release
of NO from endothelium via an activation of endothelial 5-HT1B receptors, thus attenuating its own contraction in vein
grafts. Furthermore, such SH treatment downregulates the expression of smooth muscle 5-HT2A receptors, thus further
attenuating the 5-HT-induced contraction. These novel findings further support the clinical usefulness of SH in vein
graft spasm after bypass grafting. (J Vasc Surg 2009;50:617-25.)
Clinical Relevance: It has been suggested that 5-HT plays a role in the pathogenesis of vein graft spasms. It is suggested
that smooth muscle 5-HT2A and 5-HT1B receptors contribute to 5-HT-induced contraction, while endothelial 5-HT1B
receptors contribute to the 5-HT-induced endothelium-mediated relaxation. However, it is unknown if chronic
administration of 5-HT2A receptor antagonist SHmodulates 5-HT-induced vasospasm in vein grafts. We report here that
such treatment attenuates the 5-HT-induced contraction. In addition, we demonstrate the possible underlying mecha-
nism. Because the clinical benefits and safety of sarpogrelate have been established to a certain extent through long-term
clinical usage, the study provides further evidence to support the clinical investigation of the role of sarpogrelate in vein
graft spasm after bypass grafting.The autologous vein is the optimum graft for surgical
treatment in patients suffering from peripheral arterial dis-
ease (PAD), but late graft failure remains a significant
problem, particularly under poor runoff conditions. Jiang
et al1 reported both mean flow rate and shear stress had
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doi:10.1016/j.jvs.2009.05.065been reduced throughout the 28-day perfusion period in
their model and intimal hyperplasia had been enhanced. In
such vein graft, hemodynamic factors such as low flow
velocity and low shear stress causes intima thickening and
then late graft failure.1-3
Serotonin (5-hydroxytryptamine [5-HT]) is a potent
vasospastic agent and it is believed that it plays a role in the
pathogenesis of vein graft spasms.4 It is generally thought
that 5-HT induces mechanical activities in at least two
subtypes of receptors distributed in vascular beds: 5-HT2A
receptors located in smooth muscle cells and 5-HT1B re-
ceptors distributed in both endothelial and smooth muscle
cells.5 It was found that 5-HT induced a vasoconstriction
through activation of 5-HT2A receptors in smooth muscle
cells and a vasodilatation through activation of endothelial
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rats, dogs, and pigs).5-7 On the other hand, it was found
that 5-HT induces a contraction in veins mainly through an
activation of 5-HT1 receptors.
8 However, the contributing
subtype receptors on 5-HT-induced mechanical responses
remain to be clarified in autologous vein grafts.
Sarpogrelate hydrochloride (SH) is a novel, selective
5-HT2A receptor antagonist and inhibits 5-HT-induced
platelet aggregation and smooth muscle cell proliferation.9
It has been used clinically as an anti-platelet drug for the
prevention of thrombosis in atherosclerotic disease in Ja-
pan, China, and the Republic of Korea.10,11 It was found
that in vivo administration of SH reduced intimal hyperpla-
sia in balloon-injured arteries in the hypercholesterolemic
rabbit.12 We recently found that in vivo administration of
SH inhibits intimal hyperplasia through an enhancement of
the function of endothelium-derived nitric oxide (NO) in
rabbit vein grafts.13 However, it remains unknownwhether
such treatment alters the 5-HT-induced contraction in
autologous vein grafts.
To this end, we explored this question in rabbit vein
graft under poor-runoff conditions (considered to be a
model for short-term vein graft failure). We tried to clarify
whether in vivo SH treatment alters (1) 5-HT-induced
mechanical responses; (2) the role played by endothelium-
derived NO; and (3) the expression of subtype receptors
that contribute to 5-HT-induced contraction.
METHODS
Animals. All experiments performed in this study con-
formed to guidelines on the conduct of animal experiments
issued by the Graduate School of Medical Sciences in
Nagoya City University and were approved by the Com-
mittee on the Ethics of Animal Experiments in this institu-
tion. The study also was in conformance with the publica-
tion Guiding Principles for the Care and Use of Laboratory
Animals (publication No. NIH 80-23, revised 1985).
Male Japanese white rabbits (Nippon SLC, Hamamatsu,
Japan), each weighing 2.5 to 3.0 kg, were used in this study.
The rabbits were housed individually at 20  3°C with free
access to water.
Drug administration. Rabbits were randomly di-
vided into a control group that was fed commercial rabbit
chow (CR3) (CLEA Japan Inc, Tokyo, Japan) and an
SH-treated group in which each rabbit received CR3 with
75 mg/day SH (Oriental Yeast Co, Ltd, Tokyo, Japan).
This dose of SH was based on the study by Hayashi et al.14
SH treatment was started on the day of the operation and
continued until the end of the experiment. All the rabbits
appeared to be healthy throughout the course of the study.
The rabbits which had half or less of oral intake were
omitted.
Vein graft implantation. Carotid interposition-
reversed jugular vein grafts were performed, as previously
described.13,15,16 Anesthesia was induced intramuscularly
with ketamine hydrochloride (50 mg/kg) and xylazine (10
mg/kg) and maintained with the intravenous administra-tion of ketamine hydrochloride (10 mg/kg) and xylazine
(10 mg/kg).
After a longitudinal neck incision, the right jugular vein
and the right common carotid artery were exposed. The
branches of the jugular vein were carefully ligated with 8-0
polypropylene sutures. An approximately 2.5-cm segment
of the jugular vein was taken for the autologous reversed-
vein graft. Graft harvesting was completed with meticulous
care to avoid injuring the graft wall. The harvested graft was
kept moistened in heparinized saline (5 IU/mL) at room
temperature. The animals were systemically heparinized
(200 IU/kg), and the internal carotid artery and two of
three branches of the external carotid artery were then
ligated. As Jiang et al1 previously reported, the most infe-
rior branch of the external carotid artery served as the only
outflow for the poor-runoff conditions.13,15 The common
carotid artery was clamped distally and proximally, and a
graft was anastomosed in an end-to-end fashion into the
divided artery with interrupted 8-0 polypropylene sutures
under a surgical microscope. The woundwas closed layer to
layer.
Tissue preparation. At 4 weeks after implantation,
the vein grafts were harvested under general anesthesia as
previously described.13,15 In brief, the graft was isolated
and harvested after systemic heparinization (200 IU/kg
intravenously [iv]), and the rabbits were killed by an over-
dose of pentobarbital (50 mg/kg iv). Vein grafts were
immediately excised and placed in Krebs solution and then
cleaned by removal of connective tissues. The middle por-
tion of the harvested graft was used for isometric tension
studies.
Immunohistochemical examination for 5-HT1B
and 5-HT2A receptors (Fig 1). The vein grafts were
embedded in O.C.T. compound (Tissue Tek, SAKURA
Finetechnical, Tokyo, Japan) and frozen at 80°C. Cryo-
sections were cut at 4 m thickness on a cryostat (Mic-
rotome Cryostat HM 550; MICROM International
GmbH,Walldorf, Germany), thenmounted onMatsunami
adhesive silane (MAS)-coated glass slides (Matsunami
Glass, Kishiwada, Japan) for immunohistochemistry. After
a washout with 0.01 M phosphate-buffered saline (PBS)
solution (10 mM Na2HPO4 and 250 mM NaCl, pH 7.6),
the sections were incubated at 4°C overnight with 5-HT1B
receptor rabbit antihuman polyclonal antibody (1:100 dilu-
tion; MBL International Corporation, Woburn, Mass) or
5-HT2A receptor rabbit polyclonal antibody (1:100 dilu-
tion; ImmunoStar Incorporated, Hudson, Wisc) as the
primary antibody. After the sections had been rinsed with
PBS, they were incubated with the secondary antibody
(Alexa Fluor 488 goat anti-rabbit IgG antibody; dilution
1:5000; Molecular Probes, Eugene, Ore) for 1 hour at
room temperature. After a further wash with PBS, the
fluorescence of Alexa Fluor 488 was detected by confocal-
laser-scanning microscopy (LSM5 PASCAL; Carl Zeiss,
Jena, Germany). Negative control (background staining)
data was obtained by application of second antibody only
(ie, without application of primary antibody against sub-
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from different groups of rabbits was performed under iden-
tical conditions. Fluorescent 12-bit images were acquired
and then analyzed using commercial software (LSM5
PASCAL), as previously reported.13,17 The total fluores-
cence intensities obtained from four areas (36  36 pixels
square) in each preparation were averaged, and this (ie, one
value for each value) was used for subsequent analysis.
Recording of mechanical responses. The 5-HT-
induced mechanical responses were observed using two
protocols.
Protocol 1. The vein grafts were carefully sectioned
into rings (4-5 mm long, 1 mm wide) so as not to damage
Fig 1. Immunostaining of 5-hydroxytryptamine (5-HT
group) and sarpogrelate hydrochloride (SH)-treated ra
against 5-HT1B receptors in control group (Aa) and S
medial regions. Inserted panel: Negative control data wa
application of primary antibody against each subtype o
observations were made in other three different sections f
from four samples from four different animals in eac
receptors in control group (Ba) and SH-treated group
Inserted panel: Negative control data was obtained by ap
primary antibody against each subtype of serotonin rece
data from four samples from four different rabbits in each
group (unpaired t test).the endothelium. The rings were suspended for measure-ment of isometric contraction in an organ chamber be-
tween two stainless steel wires inserted into the lumen of
the ring, one wire being connected to a force transducer
(UL-2GR; Minebea Co, Nagano, Japan) and then a carrier
amplifier (AS2101; NEC-San-ei Instruments, Tokyo, Ja-
pan). The output signal was fed into an IBM/AT-compat-
ible PC through an analog-digital converter (PowerLab;
ADInstruments Pty Ltd, Bella Vista, Australia). The organ
chamber was filled with 3 ml Krebs solution at room
temperature and gassed with 95% oxygen and 5% carbon
dioxide. The resting tension was adjusted to obtain the
maximum contraction in high K solution (128 mM).
Each preparation was allowed to equilibrate for 1 hour
ype receptors in vein grafts from control rabbits (control
(SH-treated group). A, Immunofluorescence staining
ated group (Ab). Arrow heads indicate the intima and
ined by application of second antibody only (ie, without
tonin receptors) to show background staining. Similar
hree other rabbits.Ac, Shows summary of data obtained
up. B, Immunofluorescence staining against 5-HT2A
. Arrow heads indicate the intima and medial regions.
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) to show background staining. Bc, Shows summary of
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minutes.13
The 5-HT (108-106 mol/l) was cumulatively ap-
plied from low to high concentration in both groups.
After the initial concentration-dependent response to
5-HT was obtained, the vessels were washed out three
times. Each ring was then treated with the 5-HT1B
receptor antagonist GR55562 (107 mol/l) for 15 min-
utes, and the concentration-response relationship for 5-HT
were again obtained, followed by a wash out. Finally, the
vessels were incubated with the 5-HT2A receptor antago-
Fig 2. (Protocol 1) The 5-hydroxytryptamine (5-HT)-induced
contraction in endothelium-intact vein grafts from control rabbits
(control group) and sarpogrelate hydrochloride (SH)-treated rab-
bits (SH-treated group). Effects of in vitro applied the 5-HT1B
receptor antagonist GR55562 alone and together with the
5-HT2A receptor antagonist SH in control group (A) or SH-
treated group (B). The maximum amplitude of contraction in-
duced by 5-HT (1 M) was defined as a relative tension of 1.0 for
each strip. Mean of data from six strips from six other animals, with
SEM shown by vertical line. *P  .05, **P  .01 vs none in each
group, †P  .05, ††P  .01 vs in the presence of GR55562 alone
(two-way repeated-measures analysis of variance (ANOVA) fol-
lowed by Scheffé’s post hoc F test).nist SH (107 mol/l) in the presence of GR55562 (107mol/l) for 15 minutes and the concentration-response
relationship for 5-HT were observed in the presence of
SH  GR55562 (Fig 2).
To examine the possible roles played by endothelium-
derived NO on 5-HT-induced contraction, rings with in-
tact endotheliumwere treated with the NO-synthase inhib-
itor L-NG-nitroarginine (L-NNA, 0.1 mM) for 60 minutes,
and concentration-response relationship for 5-HTwas then
observed in the presence of L-NNA. In some experiments,
the vessels were further treated with GR55562 (107
mol/l) in the presence of L-NNA and concentration-de-
pendent response to 5-HT was observed in the presence of
Fig 3. Effects of l-NG-nitroarginine (L-NNA) on 5-HT-induced
contraction in endothelium-intact vein grafts from control rabbits
(control group, A) and sarpogrelate hydrochloride (SH)-treated
rabbits (SH-treated group,B). L-NNA(), in the absence L-NNA;
L-NNA(), in presence of L-NNA; L-NNA()  GR55562, in
the presence of L-NNA and GR55562. The maximum amplitude
of contraction induced by 5-hydroxytryptamine (5-HT) (1 M)
was defined as a relative tension of 1.0 for each strip. Mean of data
from six strips from six other animals, with SEM shown by vertical
line. **P  .01 vs in the absence of L-NNA, †P  .05, vs in the
presence of L-NNA and GR55562 (two-way repeated-measures
analysis of variance [ANOVA] followed by Scheffé’s post hoc
F test).L-NNA  GR55562 (Fig 3).
A] fo
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presence of high concentrations of SH (3 M) (to exclude
any 5-HT2A-receptor mediated effects on 5-HT-induced
contraction).
After harvested vein grafts had been cut open along its
long axis using a small pair of scissors, circularly cut strips
were carefully prepared so as not to damage the endothe-
lium. In some experiments, the endothelium was carefully
removed by gentle rubbing of the intimal surface of the
vessel using small pieces of razor blade, as previously de-
scribed.13,17 Circularly cut strips (0.7-0.8 mm long, 0.2
mm wide) were mounted horizontally in a small chamber
and attached to a strain gauge (AE801; SensoNor a.s.,
Horten, Norway), allowing us to record isometric tension.
The chamber (capacity, 0.3 ml) was perfused continuously
with Krebs solution at a flow rate of 2 ml/minute. The
transducer was connected to a carrier amplifier (AS2101;
NEC-San-ei Instruments) and the output signal was fed
into an IBM/AT-compatible PC through an analog-digital
converter (PowerLab; ADInstruments Pty Ltd). The rest-
ing tension was adjusted to obtain the maximum contrac-
tion in high K solution (128 mM).
The strips were first contracted with prostaglandin F2
(PGF2, 5 M), and after the steady-state contraction had
Fig 4. (Protocol 2) Effect of L-NNA on 5-hydroxyt
control rabbits (control group) and sarpogrelate hydr
presence of sarpogrelate and prostaglandin F2 (PGF2)
SH-treated group. The 5-HTwas cumulatively applied fr
by PGF2 in the presence of SH. Summary of the effect of
(B), endothelium-intact vein grafts from SH-treated grou
group (D). L-NNA () and (), in the absence and pr
contraction induced by 5-HT (1 M) in the absence or p
each strip. Mean of data from five strips, with SEM sh
(two-way repeated-measures analysis of variance [ANOVbeen attained, 5-HT (108-106 mol/l) was cumulativelyapplied from low to high concentration. The relationship
was first observed in the absence of L-NNA and then in its
presence (Fig 4). The possible roles played by NO derived
from endothelium in the SH group was also examined by
observing the effect of 5-HT in the endothelium-denuded
strips. In some strips with intact endothelium, GR55562 (3
M) was given as pretreatment for 5 minutes in the pres-
ence of L-NNA (0.1 mM), and concentration-response
relationship for 5-HT was observed in the presence of
GR55562 L-NNA (Fig 5). Using the same experimental
systems, we previously found that acetylcholine (ACh)
induces a larger relaxation in the SH-treated group than in
the control group in endothelium-intact vein grafts.13 ACh
(1M)-induced relaxation was tested to check the function
of endothelium.
Solutions. The composition of the Krebs solution was
as follows (mM): Na 137.4; K 5.9; Mg2 1.2; Ca2 2.5;
HCO3
 15.5; H2 PO4
 1.2; Cl 134; glucose 11.5. The
solutions were bubbled with 95% oxygen and 5% carbon
dioxide. Krebs solution contained guanethidine (5 M, to
inhibit the sympathetic nerve activity).
Drugs. The drugs used in the current experiments
were as follows: SH (Tanabe-Mitsubishi Wellpharma Co,
Ltd, Osaka, Japan), 5-HT (Sigma Chemical Co, St Louis,
mine (5-HT)-induced contraction in vein grafts from
ride (SH)-treated rabbits (SH-treated group) in the
n actual trace in an endothelium-intact vein graft from
w to high concentration during the contraction induced
A in endothelium-intact vein grafts from control rabbits
) and endothelium-denuded vein grafts from SH-treated
e of L-NNA, respectively. The maximum amplitude of
ce of L-NNA was defined as a relative tension of 1.0 for
by vertical line. *P  .05 vs in the absence of L-NNA
llowed by Scheffé’s post hoc F test).rypta
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Co), L-NNA (Peptide Institute Inc, Osaka, Japan), PGF2
(Ono Pharmaceutical Co, Ltd, Osaka, Japan).
Statistical analysis. All values are expressed as means
SEM, with the n value representing the number of animals
used. Concentration-response relationships (performed in the
absence and presence of 5-HT receptor antagonist or L-
NNA with or without the antagonist) were expressed as
relative tension against the maximal responses in the ab-
sence of antagonist or L-NNA. The EC50 values were
obtained by fitting the data points for each strip by a
nonlinear least-squares method using commercial software
(OriginPro; OriginLab Co, Northampton, Mass), and
maximum response (Emax) was determined by the contrac-
tion induced by 1 M 5-HT. Statistical analysis was con-
ducted using either a two-way repeated-measures analysis
of variance (ANOVA) (followed by Sheffé’s post hoc F
test), paired t test or unpaired t test with an F test. Differ-
ences between the groups were considered to be statistically
significant when the P value was  .05.
RESULTS
All animals survived and all vein grafts were patent until
the time of harvest.
Distribution of 5-HT2A and 5-HT1B subtype re-
ceptors in vein graft. Positive immunoreactivity against
5-HT1B receptors was detected in the endothelial and
medial regions in both the control and SH-treated groups
(Fig 1, A). The density in the expression level of 5-HT1B
receptors was higher in the endothelial region than in the
medial region in both the control and SH-treated groups. In
vivo administration of SH did not modify the expression
of 5-HT1B receptors in either region in both groups (Fig
1, Ac).
The positive immunoreactivity against 5-HT2A recep-
tors was again found in endothelial and medial regions in
Fig 5. Effect of GR55562 on 5-hydroxytryptamine (5
from control rabbits (control group, A) and sarpogrelat
L-NNA and SH were present throughout the experimen
(1 M) in the absence of GR55562 was defined as a relat
with SEM shown by the vertical line. *P .05, **P .0
analysis of variance [ANOVA] followed by Scheffé’s posboth the control and SH-treated groups (Fig 1, B). Thedensity in the expression level of 5-HT2A receptors was
also higher in the endothelial region than in the medial
region in both groups. In vivo administration of SH
significantly reduced the expression of 5-HT2A receptors
not only in the endothelial region but in the medial
region as well (Fig 1, Bc).
5-HT-induced contraction in vein graft under basal
condition. (Protocol 1). The 5-HT (108-106 mol/l)
induced a concentration-dependent contraction in both
the control and SH-treated groups. The responsiveness to
5-HT was significantly less in the SH group than in the
control group (n  6, P  .05; Fig 2).
The 5-HT1B receptor antagonist GR55562 signifi-
cantly sifted the concentration-response relationship for
5-HT to the right without change in the Emax in the control
group (Fig 2, A). In contrast, it shifted the relationship to
the left with a slight increase in Emax in the SH-treated
group (Fig 2, B and Table I). The 5-HT2A receptor antag-
onist sarpogrelate attenuated the 5-HT-induced contrac-
tion in the presence of GR55562 in both groups (Fig 2).
The values of EC50 and Emax are summarized in Table I.
The NO synthase inhibitor L-NNA did not significantly
modify the 5-HT-induced contraction in the control group
(n  6, P  .24; Fig 3, A), while it significantly increased
this in the SH-treated group (n  6, P  .01; Fig 3, B). In
the presence of L-NNA, GR55562 significantly inhibited
the 5-HT-induced contraction in the SH-treated group
(n  6, P  .05).
5-HT induced contraction in the presence of sar-
pogrelate  PGF2. (Protocol 2). To further character-
ize the role played by 5-HT1B receptors on 5-HT-induced
mechanical responses, the effects of 5-HT were examined
in the presence of sarpogrelate  PGF2 in endothelium-
intact strips from the control group and in endothelium-
intact and endothelium-denuded strips from the SH-
treated group. In the presence of sarpogrelate, PGF2 (5
-induced contraction in endothelium-intact vein grafts
rochloride (SH)-treated rabbits (SH-treated group, B).
e maximum amplitude of contraction induced by 5-HT
nsion of 1.0 for each strip. Mean of data from five strips,
n the absence of GR55562 (two-way repeated-measures
F test).-HT)
e hyd
ts. Th
ive te
1 vs iM) produced a contraction in all strips from the above
ations
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5-HT (108-106 mol/l), at any given concentration, did
not induce a relaxation but produced a concentration-
dependent contraction in all strips from the three
groups. The EC50 value for 5-HT was significantly larger
in endothelium-intact strips from the SH-treated group
than in endothelium-denuded strips from the SH-
treated group or in endothelium-intact strips from the
control group (P  .01 in each case; Table II and Fig 4).
L-NNA shifted the concentration-response relationship
for 5-HT to the left in endothelium-intact strips from the
SH-treated group but this was not observed in either
endothelium-intact strips from the control group or in the
endothelium-denuded strips from the SH-treated group
(Fig 4). In the presence of L-NNA, GR55562 attenuated
the contraction induced by 5-HT in endothelium-intact
strips from both the control group (Fig 5, A) and the
SH-treated group (Fig 5, B). The EC50 values (nM) for
5-HT in the control group were 39 5 and 322 68 (n
5, P  .05) in the absence and presence of GR55562,
respectively, and Emax (mg) being 16  7 and 3  2 (n 
5, P 	 .05), respectively. In the SH-treated group, the
EC50 values (nM) for 5-HT were 50 14 and 213 38 in
the absence and presence of GR55562, respectively (n 5,
P  .01) and Emax (mg) being 34  8 and 25  8,
respectively, (n  5, P 	 .05).
DISCUSSION
We found that SH downregulated the expression of
5-HT2A receptors in the vein grafts. We also found in rabbit
autologous vein graft with poor runoff, 5-HT (108106
mol/l) induced a contraction through an activation of both
Table 1. Effect of 5-HT receptor antagonists on 5-HT-in
control rabbits (control group) and sarpogrelate hydrochlo
Control group (n  6)
EC50 (nM) E
None 158  49 12
GR55562 300  58* 8
GR55562SH 418  45* 4
*P  .05 vs none in the same group, †P  .05, ††P  .01 vs in the presenc
The results were obtained using “Protocol 1” (see “Methods” in detail).
Table 2. Effect of L-NNA on 5-HT-induced contraction
rabbits (control group) and sarpogrelate hydrochloride-tre
n Endothelium Before L-N
Control group 5  38  6
SH-treated group 5  80  9*
5  27  3‡
**P  .01 vs Control group; ††P  .01 vs before L-NNA; ‡‡P  .01 vs En
The results were obtained using “Protocol 2”. Note that the sizes of prepar5-HT1B and 5-HT2A receptors in smooth muscle cells.More importantly, we have demonstrated that chronic
administration of the 5-HT2A receptor antagonist SH up-
regulated the autoinhibitory mechanism of 5-HT through
activation of endothelial 5-HT1B receptors in the vein graft.
To our knowledge, this is the first evidence demonstrating
characteristic changes in the function of 5-HT subtype
receptors in vein grafts under poor-runoff conditions fol-
lowing chronic administration of a 5-HT2A receptor antag-
onist.
As 5-HT has been considered as one of the vasospastic
agents, it was found that a sustained supersensitivity to
5-HT is provoked in rabbit vein graft in comparison with its
control vein.18 One would think that the possible occur-
rence of vasospasm in the acute phase of vein graft (affect-
ing early graft performance) and myointimal hyperplasia at
the anastomosis and valve sites is related to vein graft
failure. Intimal hyperplasia may contribute to graft failure
by luminal narrowing and aberrant hemodynamics. Spasm
of a vessel in which the lumen has been significantly re-
duced by intimal hyperplasia may result in total occlu-
sion.19 Radic et al20 suggested that the increase in the
maximal response to serotonin paralleled the degree of
intimal hyperplasia.
The present study demonstrated the positive immuno-
reactivities against 5-HT1B receptors and 5-HT2A recep-
tors were detected in the endothelial and medial regions in
both groups. Interestingly, we found that in vivo adminis-
tration of SH reduced the expression of immunoreactive
5-HT2A receptors in vein grafts with poor runoff. It is
suggested that this may contribute to downregulation of
5-HT-induced contraction in the SH-treated group. The
underlying mechanism remains to be clarified and is a topic
d contraction in endothelium-intact vein grafts from
-treated rabbits (SH-treated group)
SH-treated group (n  6)
g) EC50 (nM) Emax (mg)
49 245  35 81  28
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R55562 in the same group.
in grafts with or without endothelium from control
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were different with those in “Protocol 1”. (see “Methods” in detail).duce
ride
max (m
8 
5 
0 
e of Gin ve
ated
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*
‡
dothefor future study.
JOURNAL OF VASCULAR SURGERY
September 2009624 Kodama et alIn endothelium-intact vein graft with poor runoff, we
found that (1) the 5-HT2A receptor antagonist SH inhib-
ited 5-HT-induced contraction in the presence of the
5-HT1B receptor antagonist GR55562 (Fig 2) and (2)
GR55562 inhibited the 5-HT-induced contraction in the
presence of SH together with the NO synthase inhibitor
L-NNA (Fig 5). These results indicate that in rabbit vein
grafts with poor runoff, 5-HT induces a constriction
through an activation of both 5-HT1B and 5-HT2A recep-
tors located in smooth muscle cells.
We previously found that ACh-induced endothelium-
dependent relaxation in vein graft from the SH-treated
group (not in the control group) and that the ACh-induced
response is completely blocked by L-NNA,13 indicating
that chronically administered SH increases endothelial NO
release by some endothelial stimulants. It is suggested that
5-HT enhances NO production via activation of endothe-
lial 5-HT1B subtype receptors in pig and dog isolated
coronary artery.7,21 We found that (1) the presence of
5-HT1B receptors was identified in the endothelium of vein
grafts (Fig 1, A) and its expression level was not modified
by in vivo administration of SH; (2) the 5-HT1B receptor
blocker GR55562 enhanced 5-HT-induced contraction
in the SH-treated group while this inhibited the 5-HT-
induced one in the control group (Fig 2); and (3) the
enhancement action by GR-55562 in the SH-treated
group was not seen in the presence of L-NNA (Fig 3, B).
Taken together, these evidences suggest that in the SH-
treated group, 5-HT1B receptors may contribute to 5-HT-
induced NO release in rabbit vein grafts, thus attenuating
the 5-HT-induced contraction. The mechanism underly-
ing the 5-HT1B-induced endothelium NO release re-
mains to be obscure. This should be clarified in future
experiments. However, several studies have demon-
strated the importance of preserving the function of
endothelium-derived NO in order to inhibit the devel-
opment of intimal hyperplasia of autologous vein
graft.22,23 An increase in NO production in this experi-
mental model might lead to a reduction of intimal hy-
perplasia.
Several studies demonstrated that SHmay be of benefit
for patients with PAD.Norgen et al24 reported SHwas well
tolerated and showed an increased absolute walking dis-
tance. Miyazaki et al11 reported oral administration of SH
improved forearm and leg blood flow response to reactive
hyperemia (an index of endothelium-dependent vasodi-
lation). SH has been used for years to treat patients with
PAD and has been well tolerated. The major side effect
of SH is a bleeding tendency due to its antithromboge-
nicity. Several reports showed few major side effects in
PAD.25-27 These results suggest the clinical usefulness of
this agent for preventing intimal hyperplasia in vein graft
after bypass grafting in patients with PAD. Clinical stud-
ies with large number of patients in a double-blind,
randomized, placebo-controlled conditions are needed
to confirm the present hypothesis.CONCLUSION
We demonstrated that in rabbit vein grafts with poor
runoff, 5-HT induces a concentration-dependent contrac-
tion through activations of smooth muscle 5-HT1B and
5-HT2A receptors. Chronic in vivo administration of SH
attenuates the 5-HT-induced contraction through (1) a
release of NO from the endothelium via an activation of
endothelial 5-HT1B receptors and (2) downregulation of
smooth muscle 5-HT2A receptors. Further scientific and
clinical studies are required to evaluate the possible benefits
of SHmay have on bypass grafts with respect to vasospasm,
function, and patency.
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